dc.contributor.author |
Grabowski, Henry G |
|
dc.contributor.author |
Wang, Y Richard |
|
dc.coverage.spatial |
United States |
|
dc.date.accessioned |
2013-04-23T17:03:00Z |
|
dc.date.issued |
2006-03 |
|
dc.identifier |
https://www.ncbi.nlm.nih.gov/pubmed/16522586 |
|
dc.identifier |
25/2/452 |
|
dc.identifier.uri |
https://hdl.handle.net/10161/6725 |
|
dc.description.abstract |
We examined trends in the introduction of new chemical entities (NCEs) worldwide from
1982 through 2003. Although annual introductions of NCEs decreased over time, introductions
of high-quality NCEs (that is, global and first-in-class NCEs) increased moderately.
Both biotech and orphan products enjoyed tremendous growth, especially for cancer
treatment. Country-level analyses for 1993-2003 indicate that U.S. firms overtook
their European counterparts in innovative performance or the introduction of first-in-class,
biotech, and orphan products. The United States also became the leading market for
first launch.
|
|
dc.language |
eng |
|
dc.publisher |
Health Affairs (Project Hope) |
|
dc.relation.ispartof |
Health Aff (Millwood) |
|
dc.relation.isversionof |
10.1377/hlthaff.25.2.452 |
|
dc.subject |
Biotechnology |
|
dc.subject |
Drug Industry |
|
dc.subject |
Drugs, Investigational |
|
dc.subject |
Europe |
|
dc.subject |
Global Health |
|
dc.subject |
Humans |
|
dc.subject |
Investigational New Drug Application |
|
dc.subject |
Orphan Drug Production |
|
dc.subject |
United States |
|
dc.title |
The quantity and quality of worldwide new drug introductions, 1982-2003. |
|
dc.type |
Journal article |
|
duke.contributor.id |
Grabowski, Henry G|0099498 |
|
pubs.author-url |
https://www.ncbi.nlm.nih.gov/pubmed/16522586 |
|
pubs.begin-page |
452 |
|
pubs.end-page |
460 |
|
pubs.issue |
2 |
|
pubs.organisational-group |
Duke |
|
pubs.organisational-group |
Economics |
|
pubs.organisational-group |
Trinity College of Arts & Sciences |
|
pubs.publication-status |
Published |
|
pubs.volume |
25 |
|
dc.identifier.eissn |
1544-5208 |
|